What Is Bioidentical Hormone Therapy for Men?

Defining Bioidentical Hormones in Male HRT

Bioidentical hormones are synthesized in a laboratory to match the exact molecular structure of hormones produced by the human body. For men, the primary bioidentical hormone is testosterone (C₁₉H₂₈O₂). The starting material is typically diosgenin extracted from wild yam or soy, which undergoes chemical conversion into testosterone or one of its esterified forms 1.

How "Bioidentical" Differs from "Synthetic"

The term "bioidentical" distinguishes these hormones from synthetic androgens like methyltestosterone, which carry a 17-alpha-alkyl group that alters hepatic metabolism and raises liver toxicity risk. Bioidentical testosterone cypionate and enanthate lack this modification. They are metabolized through the same pathways as endogenous testosterone 2.

The Compounded vs. FDA-Approved Distinction

A common source of confusion: all FDA-approved testosterone products (AndroGel, Testopel, Depo-Testosterone) are already bioidentical. The marketing term "bioidentical" often gets attached exclusively to compounded preparations, but this is misleading. The Endocrine Society's 2018 scientific statement noted that "there is no evidence that custom-compounded bioidentical hormones are safer or more effective than FDA-approved formulations" 3. The distinction is regulatory and pharmaceutical, not molecular.

Why Men Seek Bioidentical Testosterone Therapy

Male hypogonadism affects an estimated 20% to 40% of men over age 45, depending on the diagnostic threshold applied 4. Symptoms include persistent fatigue, reduced libido, erectile dysfunction, depressed mood, decreased muscle mass, and increased visceral fat. These symptoms overlap with aging, which makes diagnosis reliant on both clinical presentation and confirmed low morning serum testosterone on two separate occasions.

AUA Diagnostic Criteria

The American Urological Association defines low testosterone as a total testosterone level below 300 ng/dL, measured between 8:00 and 10:00 AM 5. The Endocrine Society uses the same cutoff but emphasizes that free testosterone or bioavailable testosterone should be measured when total testosterone falls between 200 and 400 ng/dL and SHBG abnormalities are suspected.

Symptom Relief Timelines

Not all benefits arrive on the same schedule. A meta-analysis published in the European Journal of Endocrinology mapped the timeline: sexual interest improves within 3 to 6 weeks, with a plateau at 6 months; erections and ejaculatory function may require up to 6 months; improvements in depressive symptoms appear at 3 to 6 weeks, maximal at 18 to 30 weeks; and changes in fat mass, lean body mass, and muscle strength become measurable at 12 to 16 weeks, stabilizing around 6 to 12 months 6.

FDA-Approved Bioidentical Testosterone Formulations

Every FDA-approved testosterone product on the U.S. Market is bioidentical by molecular definition. The differences lie in delivery method, pharmacokinetics, and cost.

Injectable Esters

Testosterone cypionate (Depo-Testosterone) and testosterone enanthate are the most commonly prescribed formulations. Typical dosing is 100 to 200 mg intramuscularly every 1 to 2 weeks, or 50 to 80 mg subcutaneously twice weekly for more stable serum levels. A 10 mL vial of generic testosterone cypionate (200 mg/mL) costs approximately $30 to $75 at retail pharmacies 7.

Topical Gels and Solutions

AndroGel 1% and 1.62%, Testim 1%, and Vogelxo deliver testosterone transdermally. Serum levels reach steady state within 24 to 48 hours. The primary risk unique to gels is secondary transfer to women or children through skin contact, which prompted an FDA black box warning 7. Monthly costs range from $200 to $500 without insurance for branded products.

Pellets, Patches, and Newer Routes

Testopel subcutaneous pellets (75 mg each, typically 8 to 14 pellets) are implanted every 3 to 6 months and provide steady testosterone release. Androderm transdermal patches deliver 2 to 4 mg daily but cause skin irritation in up to 60% of users. Natesto nasal gel (5.5 mg per nostril, three times daily) offers a short-acting option that may have less suppressive effects on spermatogenesis 8. Jatenzo (testosterone undecanoate oral capsule) received FDA approval in 2019, dosed at 158 to 396 mg twice daily with food, avoiding first-pass hepatotoxicity through lymphatic absorption 9.

Compounded Bioidentical Testosterone: What to Know

Compounded testosterone products are prepared by 503A (individual prescription) or 503B (outsourcing facility) pharmacies. They include custom-dose creams, sublingual troches, and pellets.

Potential Advantages

Compounding allows for dose customization that branded products cannot match. A man who needs 7.5% testosterone cream or a pellet dose between standard increments may benefit. Some clinicians also compound testosterone with chrysin or anastrozole to manage estradiol conversion in a single preparation 10.

Risks and Regulatory Gaps

Compounded products do not undergo FDA premarket review for safety, efficacy, or consistency. A 2018 JAMA Internal Medicine investigation found that 34 of 48 compounded hormone therapy products tested (71%) failed potency or sterility standards 11. The FDA has issued multiple warning letters to compounding pharmacies for contamination and superpotent or subpotent preparations. Dr. Shalender Bhasin, director of the Research Program in Men's Health at Brigham and Women's Hospital, has stated: "FDA-approved testosterone formulations have well-characterized pharmacokinetics and safety profiles that compounded preparations simply do not" 3.

Clinical Evidence: Testosterone Trials Hub (TTrials)

The Testosterone Trials (TTrials) remain the largest coordinated set of placebo-controlled studies in older men with low testosterone. Seven trials enrolled 788 men aged 65 and older with serum testosterone below 275 ng/dL and symptoms in at least one domain 12.

Key Outcomes

In the Sexual Function Trial, testosterone gel increased the Psychosexual Daily Questionnaire (PDQ) sexual desire score by 2.93 points versus placebo (P<0.001) and sexual activity by 0.58 activities per day. The Physical Function Trial showed a modest but statistically significant improvement in the 6-minute walk distance (mean gain: 6.1 meters over placebo). The Vitality Trial did not reach its primary endpoint on the FACIT-Fatigue scale, though a secondary SF-36 vitality domain analysis favored testosterone 12.

Cardiovascular and Bone Findings

The Cardiovascular Trial detected increased noncalcified coronary plaque volume in the testosterone group (an absolute increase of 41 mm³ vs. 14 mm³ in placebo) over 12 months, raising concern that required longer-term data 13. The Bone Trial showed testosterone increased volumetric bone mineral density at the spine by 7.5% and estimated bone strength by 10.8% over 12 months 14.

TRAVERSE Trial: Cardiovascular Safety Data

The TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men) was a randomized, double-blind, placebo-controlled, noninferiority trial of 5,246 men aged 45 to 80 with hypogonadism and preexisting or high risk of cardiovascular disease 15.

Primary Result

Over a mean follow-up of 33 months, the primary composite endpoint of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke occurred in 7.0% of the testosterone group versus 7.3% in the placebo group (hazard ratio 0.96; 95% CI, 0.78 to 1.17), meeting the noninferiority margin. This trial was published in the New England Journal of Medicine in June 2023 and reshaped clinical confidence in testosterone therapy for men with cardiovascular risk factors 15.

Limitations Worth Noting

TRAVERSE excluded men with recent stroke, MI within the prior 3 months, or NYHA class III/IV heart failure. The incidence of pulmonary embolism was higher in the testosterone group (0.9% vs. 0.5%). Clinicians should still assess venous thromboembolism risk before initiating therapy.

Monitoring and Safety Protocol

The Endocrine Society and AUA both recommend a structured monitoring protocol for men on testosterone therapy 5.

Baseline Labs

Before starting therapy: morning total testosterone (two measurements), free testosterone or SHBG, complete blood count (CBC), comprehensive metabolic panel, lipid panel, PSA, and estradiol. A digital rectal exam is recommended for men over 40.

Follow-Up Schedule

At 6 weeks: check trough total testosterone (target 450 to 700 ng/dL), hematocrit, and estradiol. At 3 to 6 months: repeat testosterone, CBC, PSA, lipid panel. Annually thereafter: full panel including PSA, hematocrit, liver function, and metabolic markers. Hematocrit above 54% warrants dose reduction, phlebotomy, or temporary discontinuation 16.

Fertility Considerations

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing intratesticular testosterone and impairing spermatogenesis. Recovery after cessation typically takes 6 to 12 months but can be incomplete. Men desiring future fertility should consider alternatives such as clomiphene citrate (off-label), enclomiphene, or human chorionic gonadotropin (hCG) as monotherapy or adjunct to lower-dose testosterone 17.

BHRT Beyond Testosterone: DHEA and Pregnenolone

Some clinicians include DHEA (dehydroepiandrosterone) or pregnenolone in male BHRT protocols, though evidence supporting their addition is limited.

DHEA

DHEA is available over the counter as a dietary supplement. A 2013 meta-analysis of 25 randomized trials found no consistent benefit of DHEA supplementation on body composition, physical performance, lipid profiles, or glucose metabolism in men 18. The Endocrine Society recommends against routine DHEA supplementation for age-related androgen decline.

Pregnenolone

Pregnenolone is a neurosteroid precursor with proposed cognitive and mood benefits. Clinical trial data in healthy men are sparse. No FDA-approved pregnenolone product exists for hypogonadism, and its inclusion in BHRT protocols is based on theoretical rationale rather than controlled evidence 19.

Choosing Between Bioidentical Options

The choice of formulation depends on patient preference, insurance coverage, needle comfort, lifestyle, and fertility goals.

Decision Factors

Injectable cypionate or enanthate offers the lowest cost and most predictable dose-response relationship. Gels provide steady daily levels without injections but carry transfer risk and higher cost. Pellets reduce visit frequency to two to four times per year but require a minor surgical procedure and do not allow rapid dose adjustment. Nasal testosterone (Natesto) may partially preserve spermatogenesis but requires three-times-daily dosing. Jatenzo oral capsules avoid injections and transfer risk but must be taken with a fat-containing meal and carry a black box warning for blood pressure elevation 9.

When to Avoid Testosterone Entirely

Absolute contraindications per the AUA include: breast or prostate cancer (active, suspected), hematocrit above 50% at baseline, untreated severe obstructive sleep apnea, uncontrolled heart failure, desire for fertility in the near term, and PSA above 4 ng/mL without urological evaluation 5. As Dr. Abraham Morgentaler, associate clinical professor of urology at Harvard Medical School, has noted: "The old belief that testosterone fuels prostate cancer has been replaced by a more nuanced understanding, but active prostate cancer remains a clear contraindication."

What the Guidelines Recommend

Both the AUA (2018) and the Endocrine Society (2018) endorse testosterone therapy for men with symptomatic hypogonadism confirmed by two low morning testosterone levels. Neither guideline distinguishes between "bioidentical" and "non-bioidentical" testosterone, because all approved formulations are molecularly identical to endogenous testosterone 5 16.

The AUA explicitly states that testosterone therapy should not be initiated solely to improve body composition or cognitive function in men with normal testosterone levels. The goal is symptom resolution with the lowest effective dose, monitored through regular bloodwork and clinical assessment.

Men starting bioidentical testosterone should expect a baseline blood draw, a follow-up at 6 weeks to verify trough levels are between 450 and 700 ng/dL, hematocrit rechecked at 3 and 6 months, and PSA tracked annually for men over 40.